Volume 60, Issue 4, Pages (October 2001)

Slides:



Advertisements
Similar presentations
Kamyar Kalantar-Zadeh  Kidney International 
Advertisements

Volume 59, Issue 3, Pages (March 2001)
Nina Vasavada, Rajiv Agarwal  Kidney International 
Volume 63, Issue 3, Pages (March 2003)
Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors  George L. Bakris, M.D, Nancy A. Lass, Dana Glock 
Paul W. Eggers, Dorothy Gohdes, Jacqueline Pugh  Kidney International 
Sushrut S. Waikar, Venkata S. Sabbisetti, Joseph V. Bonventre 
From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria  Paul E. De Jong, Barry M. Brenner  Kidney International 
Paul W. Eggers, Dorothy Gohdes, Jacqueline Pugh  Kidney International 
Volume 59, Issue 1, Pages (January 2001)
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 88, Issue 2, Pages (August 2015)
‘Progressive diabetic nephropathy. How useful is microalbuminuria
Volume 54, Issue 2, Pages (August 1998)
Better nephrology for mice—and man
Volume 77, Issue 8, Pages (April 2010)
Kamyar Kalantar-Zadeh  Kidney International 
The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age  B.O. Eriksen, O.C. Ingebretsen  Kidney International 
Volume 69, Issue 11, Pages (June 2006)
Volume 77, Issue 1, Pages 5-6 (January 2010)
Volume 55, Issue 1, Pages (January 1999)
Volume 67, Issue 3, Pages (March 2005)
Volume 61, Issue 6, Pages (June 2002)
Volume 76, Issue 3, Pages (August 2009)
Volume 87, Issue 2, Pages (February 2015)
Enlightenment on liver lanthanum exposure
Volume 59, Issue 3, Pages (March 2001)
Volume 68, Issue 6, Pages (December 2005)
Volume 65, Issue 2, Pages (February 2004)
Volume 81, Issue 5, Pages (March 2012)
Fabia M.O. Pinho, Dirce M.T. Zanetta, Emmanuel A. Burdmann 
Volume 66, Issue 2, Pages (August 2004)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 63, Pages S38-S42 (February 2003)
Volume 64, Issue 1, Pages (July 2003)
Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske 
Volume 85, Issue 5, Pages (May 2014)
Methods for guideline development
Volume 56, Issue 2, Pages (August 1999)
Volume 67, Issue 4, Pages (April 2005)
Citrate therapy for polycystic kidney disease in rats
Volume 68, Issue 4, Pages (October 2005)
Volume 57, Issue 1, Pages (January 2000)
Volume 60, Issue 1, Pages (July 2001)
Douglas G Matsell, Colin T White  Kidney International 
Volume 69, Issue 5, Pages (March 2006)
Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita  Kidney International 
Evidence for impaired assimilation of protein in chronic renal failure
Volume 67, Issue 4, Pages (April 2005)
Nina Vasavada, Rajiv Agarwal  Kidney International 
Volume 80, Issue 10, Pages (November 2011)
Volume 81, Issue 7, Pages (April 2012)
Volume 72, Issue 11, Pages (December 2007)
Volume 64, Issue 2, Pages (August 2003)
Renal actions of synthetic Dendroaspis natriuretic peptide
MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis  Antonio Guasch, M.D., Carlos F. Zayas, Kamal.
Volume 56, Issue 4, Pages (October 1999)
Volume 62, Issue 5, (November 2002)
Volume 58, Issue 2, Pages (August 2000)
Volume 61, Issue 1, Pages (January 2002)
Volume 53, Issue 5, Pages (May 1998)
Rebound kinetics of β2-microglobulin after hemodialysis
Volume 69, Issue 11, Pages (June 2006)
Volume 58, Issue 5, Pages (November 2000)
Temporal adaptation of tubuloglomerular feedback: Effects of COX-2
Podocytopenia and disease severity in IgA nephropathy
Volume 63, Issue 3, Pages (March 2003)
The Ebf1 knockout mouse and glomerular maturation
Volume 79, Issue 10, Pages (May 2011)
Presentation transcript:

Volume 60, Issue 4, Pages 1258-1265 (October 2001) Effects of C-peptide on glomerular and renal size and renal function in diabetic rats  Björn Samnegård, Stefan H. Jacobson, Georg Jaremko, Bo-Lennart Johansson, Mats Sjöquist  Kidney International  Volume 60, Issue 4, Pages 1258-1265 (October 2001) DOI: 10.1046/j.1523-1755.2001.00964.x Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 Glomerular volume 14 days after the start of treatment. Tukey box and whisker plot. The symbol (□) indicates the median value, while the outer boxes represent the 25th and the 75th percentiles and whiskers show the non-outlier range. A value was defined as an out-lier if it was more than 1.5 times the box height above or below the box. Analysis of variance followed by the Tukey post hoc test was used for the statistical analysis. Asterisks indicate statistically significant differences between groups (***P <0.001) and NS is nonsignificant. Kidney International 2001 60, 1258-1265DOI: (10.1046/j.1523-1755.2001.00964.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 2 Glomerular filtration rate (GFR) 14 days after the start of treatment. GFR was measured as clearance of inulin, before infusion of glycine was started. Tukey box and whisker plot. The symbol (□) indicates the median value, while the outer box represents the 25th and the 75th percentiles and whiskers show the non-outlier range. A value was defined as an outlier if it was more than 1.5 times the box height above or below the box. Analysis of variance followed by Tukey's post hoc test was used for the statistical analysis. Asterisks indicate statistically significant differences between groups (***P <0.001) and NS is nonsignificant. Kidney International 2001 60, 1258-1265DOI: (10.1046/j.1523-1755.2001.00964.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 3 Glomerular filtration rate (GFR) 14 days after treatment start, before, and during glycine infusion. GFR was measured as clearance of inulin. Symbols are: (▴) normal group, N = 7; (□) D-C-p group, N = 7; (▪) D-placebo group, N = 7. Analysis of variance for repeated measurements followed by the Tukey post hoc test was used for the statistical analysis. Statistically significant differences, within one group, from the basal state (before glycine infusion) are shown as **P <0.01 and ***P <0.001. Data are shown as means ± SEM. Kidney International 2001 60, 1258-1265DOI: (10.1046/j.1523-1755.2001.00964.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 4 Urinary albumin excretion days 0, 4, 8, and 12 after treatment start. Symbols are (▴) normal group, N = 7; (□) D-C-p group, N = 7; (▪) D-placebo group, N = 7. Analysis of variance for repeated measurements followed by the Tukey post hoc test was used for the statistical analysis after the values had been logarithmically transformed. Asterisks indicate statistically significant differences from the basal state within each group: *P <0.05; **P <0.01. Data are shown as means ± SEM. Kidney International 2001 60, 1258-1265DOI: (10.1046/j.1523-1755.2001.00964.x) Copyright © 2001 International Society of Nephrology Terms and Conditions